Ibrahim T. Aldoss, MD, of City of Hope Comprehensive Cancer Center, discusses the potential of revumenib in KMT2A-rearranged (KMT2Ar) acute leukemias, with pivotal results presented at the 65th Annual American Society of Hematology Annual Meeting and Exposition this week.
Ibrahim T. Aldoss, MD, a hematologist/oncologist at City of Hope National Medical Center, discusses the potential of oral menin inhibitor revumenib in KMT2A-rearranged (KMT2Ar) acute leukemias, with pivotal phase 2 results from the AUGMENT-01 trial presented at the 65th Annual American Society of Hematology Annual Meeting and Exposition this week.
Promising pivotal results from an interim efficacy analysis showed a composite complete response rate of 43.9% (95% CI, 30.7-57.6) and an overall response rate of 63.2% (95% CI, 49.3-75.6).
Transcript
Can you speak to the need for targeted therapies to treat relapsed/refractory KMT2A-rearranged acute leukemia?
In previous studies for patients with similar characteristics to these patients who were receiving their second or beyond salvage therapy, the overall response rate for these relapsed refractory patients with KMT2A was lower than 10%, and the median overall survival was below 3 months. It's truly an area with unmet therapeutic need, where we need some targeted therapy that improves outcomes for these patients, because current standard treatments are ineffective at improving the outcomes of these patients. So, we're very excited about the results of revumenib in this difficult-to-treat population: heavily pretreated patients where we show the majority are responding, the responses are durable and deep, and we're able to transition these patients to transplant.
What sets revumenib apart from current standard treatments in this setting, and might it be integrated into practice if it is approved?
Revumenib is different than the current standard of therapy in this disease as the current standard therapy is only chemotherapy, and we know from previous studies it is highly ineffective in inducing remission. They're more toxic, and for patients who achieve remission, the duration of remission is very short. Revumenib is a targeted therapy based on preclinical studies. We're targeting what drives the leukemia in this kind of disease. So, with being effective and safe, the idea is how we can combine it with what we consider standard of care in the relapsed or refractory setting as well as newly diagnosed patients, with more interest early in the treatment paradigm of these patients, so we can improve the outcomes of those patients.
Reference
Caffrey M. Pivotal results show revumenib holds promise for patients with KMT2Ar acute leukemia. AJMC. December 12, 2023. Accessed December 12, 2023. https://www.ajmc.com/view/pivotal-results-show-revumenib-holds-promise-for-patients-with-kmt2ar-acute-leukemia
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More